Lisata Therapeutics sues Kuva Labs over breached merger agreement, seeks $2 million fee

• Lisata Therapeutics filed suit in Delaware Chancery Court against Kuva Labs over an alleged breach of the March 6, 2026 merger agreement.
• The complaint seeks damages for stockholders, including a USD 2 million termination fee under the merger agreement.
• The litigation follows termination of the merger agreement with Kuva Labs and its Kuva Acquisition unit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802924) on August 04, 2026, and is solely responsible for the information contained therein.